Pages that link to "Q46142456"
Jump to navigation
Jump to search
The following pages link to The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. (Q46142456):
Displaying 17 items.
- Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs (Q26774750) (← links)
- Differential expression of cytochrome P450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma (Q31155554) (← links)
- Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry (Q35209694) (← links)
- Cancer cell spheroids as a model to evaluate chemotherapy protocols (Q36312156) (← links)
- Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone (Q36573248) (← links)
- TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. (Q37700855) (← links)
- Hypoxia-activated prodrugs in cancer therapy: progress to the clinic (Q37707385) (← links)
- Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase (Q38722296) (← links)
- Hypoxia-responsive nanocarriers for cancer imaging and therapy: recent approaches and future perspectives (Q38844453) (← links)
- Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. (Q39150971) (← links)
- Antiangiogenesis enhances intratumoral drug retention (Q39568663) (← links)
- Smart Cu(II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma. (Q40203410) (← links)
- Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy (Q46922239) (← links)
- Chemotherapeutic Drug Based Metal-Organic Particles for Microvesicle-Mediated Deep Penetration and Programmable pH/NIR/Hypoxia Activated Cancer Photochemotherapy. (Q52605912) (← links)
- Phenazine N,N′-dioxide scaffold as selective hypoxic cytotoxin pharmacophore. Structural modifications looking for further DNA topoisomerase II-inhibition activity (Q58869691) (← links)
- pH/hypoxia programmable triggered cancer photo-chemotherapy based on a semiconducting polymer dot hybridized mesoporous silica framework (Q90442215) (← links)
- Nuclear cytometry and chromatin organization (Q91136869) (← links)